Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Conditions
- Platinum-resistant Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
- Interventions
- Biological: PembrolizumabBiological: NemvaleukinBiological: Nemvaleukin and Pembrolizumab Combination
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 456
- Registration Number
- NCT05092360
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
- Conditions
- Cutaneous MelanomaMucosal Melanoma
- Interventions
- Drug: Nemvaleukin Alfa SubcutaneousDrug: Nemvaleukin Alfa IntravenousDrug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 173
- Registration Number
- NCT04830124
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 78
- Registration Number
- NCT04592653
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸START Mountain, West Valley City, Utah, United States
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT04144517
- Locations
- 🇺🇸
Mural Oncology Investigational Site, Austin, Texas, United States
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 116
- Registration Number
- NCT03861793
- Locations
- 🇨🇳
Mural Oncology Investigational Site, Taipei, Taiwan
🇨🇦Mural Oncology Investigational Sites, Montréal, Quebec, Canada
🇰🇷National Cancer Center, Goyang, Korea, Republic of
- Prev
- 1
- 2
- Next
News
Mural Oncology Cuts 90% of Workforce Following Failed Cancer Immunotherapy Trials
Mural Oncology is discontinuing all clinical development of nemvaleukin alfa after the immunotherapy failed to meet target goals in melanoma and ovarian cancer trials.
Mural Oncology Gears Up for Key Data Readouts of Nemvaleukin in Ovarian Cancer and Melanoma in 2025
Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events.
Nemvaleukin Shows Promising Antitumor Activity in Advanced Solid Tumors
Nemvaleukin, an engineered IL-2 fusion protein, demonstrates tolerability and antitumor activity in the ARTISTRY-1 phase 1/2 trial, both as monotherapy and in combination with pembrolizumab.
Mural Oncology's Nemvaleukin Trials Progressing, Data Readouts Anticipated in 2025
Mural Oncology remains on track with late-stage trials for nemvaleukin alfa, expecting data readouts for platinum-resistant ovarian cancer in late Q1/early Q2 2025.
Mural Oncology Highlights Nemvaleukin Progress and IL-18 Program at Investor Day
Mural Oncology's ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab in platinum-resistant ovarian cancer, anticipates interim data in early Q2 2025.